### **Trans Mountain Expansion Project**

## Annex 1: Socio-Economic Context Indicators - Hinton to Hargreaves Reactivation

#### As of December 31, 2022

Based on government and public sources

# TRANSMOUNTAIN

#### Introduction

This report presents the context indicators associated with the TMEP Hinton to Hargreaves Reactivation Region, updated to reflect the October to December (Q4) 2022 monitoring period. These data are from public and government sources. They reflect the overall social and economic context within which Project construction is occurring and present a picture of the overall social and economic resiliency of the region related to the socio-economic monitoring topic areas. Data is being reported for the entire region, even though construction activity may only be occurring in a select portion of the region. These data will be updated during Project construction when new data becomes available. This report also provides a one-time update of select community-level data points for communities crossed by the Project footprint have been updated since the finalization of the Socio-Economic Effects Monitoring Plan based on the 2016 Census of Canada; this data is only updated every 5 years, so will not be updated during the Project construction period.

#### **One-time Community Level Data**

-		Population and Dwelli		Housing		Labour				
Community	Population 2016 (No.)	Population Change from Last Census (2011) (%)	Percentage of Population that Identifies as Aboriginal (%)	Total Private Dwellings (No.)	Percentage of Private Dwellings Occupied by Usual Residents (%)	Average Value of Dwelling (\$)	Labour Force Size (No.)	Participation Rate (%)	Unemployment Rate (%)	Labour Force by Industry (%) (top 3 industries)
Municipality of Jasper	4509	3.6	2.1	1702	92.5	\$ 583,236	2495	79.4	5.8	Accommodation & food services (28.7%) Arts, entertainment & recreation (11.8%) Transportaion & warehousing (10.8%)
ID No. 12	53	55.9	X	X	F	Х	Х	X	Х	x

X - area and value supression

#### **Context Indicators**

In this region, the Project is occurring in a predominantly rural area. The population of the communities traversed by the Project in this region is over 4,500 with a labour force of approximately 2,500, with a wider regional population of approximately 270,000 and regional labour force of over 180,000. TMEP is the only major project identified in this region. The current and anticipated Project workforce is small in the context of this region.

Context Indicator	Date	Data Description
Population		
Population (No.)		
Banff-Jasper-Rocky Mountain House and Athabasca-Grande Prairie-Peace River Economic Region	Oct-22	The total population was 279,100, which is a 0.4% increase from August 2022.
Labour Force		
Labour force size (No.):		
Banff-Jasper-Rocky Mountain House and Athabasca-Grande Prairie-Peace River Economic Region	Oct-22	The labour force size was 192,000, which is a 1.6% increase from August 2022.
Participation Rate (%)		
Banff-Jasper-Rocky Mountain House and Athabasca-Grande Prairie-Peace River Economic Region	Oct-22	The participation rate was 68.9%, which is higher than the participation rate reported in August 2022 (68.1%).
Unemployment Rate (%)		
Banff-Jasper-Rocky Mountain House and Athabasca-Grande Prairie-Peace River Economic Region	Oct-22	The unemployment rate was 5.7%, which is higher than the unemployment rate reported in August 2022 (5.4%).
Major projects (\$ capital investment)	Dec-22	One major project was identified as under construction in the Hinton to Hargreaves Reactivation Region, with a total capital cost of approximately \$21.4 billion. The only project with large (>\$1 billion) capital costs is the Trans Mountain Pipeline Expansion.

F - data too unreliable to publish

Accommodation  Rental vacancy rates (9)			
Rental vacancy rates (9			
Municipality of Jasper	2021	The vacancy rate was 0% in p	ivate apartments.
Rent by rental type (\$/month, by			
Municipality of Jasper	2021	The average rents for a privat	e apartment range from \$911 for a bachelor, to \$1,335 for 4 bedroom +.
Crime/Policing			
		Rate per 1,000 population,	
Incident Category		by Police Service Area	
	•	Jasper RCMP, rural	
Total violent Criminal Code Violations	2021	17.4	
Sexual assault, level 1, 2 and 3	2021	0.707	
Total commodification of sexual activity	2024		
violations	2021	n/a	
Total Property Crime Violations	2021	38.9	
	2024		
Total Other Criminal Code Violation (Except Traffic)	2021	13	
Total prostitution	2021	0.000	
Total Criminal Code Traffic Violations	2021	8.7	
Total Drug Violations	2021	2.6	
Traffic	2021	2.0	
Annual Average Daily Traffic (AADT) – Location			
50160010, Highway 16	Nov-22	The two-way AADT at this tra	ffic count site was 2,522 in November 2022. From the staging area, Project vehicles may travel west on Highway 16.
Communicable Diseases			
		No. of Cases	
		North Health Zone	
Disease	Surveillance Date	(North Health Zone	
		Southwest for Sexually	
		Transmitted Infections)	
Coronavirus - COVID 19	2023 (as of January 9th)	66,917 (confirmed cases)	
Amoebiasis	l		
	12020	3 (0.62 per 100 000)	
Campylohacteriosis	2020	3 (0.62 per 100,000) 106 (22 04 per 100 000)	
Campylobacteriosis	2020	106 (22.04 per 100,000)	
Cryptosporidiosis	2020 2020	106 (22.04 per 100,000) 7 (1.46 per 100,000)	
Cryptosporidiosis E.Coli	2020 2020 2020	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis	2020 2020 2020 2020	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 26 (5.41 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive	2020 2020 2020 2020 2020 2020	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 26 (5.41 per 100,000) 5 (1.04 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A	2020 2020 2020 2020 2020 2020 2020	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 26 (5.41 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis A Acute Cases	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 26 (5.41 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 6 (1.25 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 26 (5.41 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 6 (1.25 per 100,000) 17 (3.53 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 26 (5.41 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 6 (1.25 per 100,000) 1 (0.23 per 100,000) 1 (0.21 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Acute Cases	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 6 (1.25 per 100,000) 17 (3.53 per 100,000) 1 (0.21 per 100,000) 1 (0.31 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Acute Cases Hepatitis C Carrier Status Unknown	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 6 (1.25 per 100,000) 17 (3.53 per 100,000) 1 (0.21 per 100,000) 16 (3.33 per 100,000) 6 (3.33 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Acute Cases Hepatitis C Catrier Status Unknown Hepatitis C Corrier Status Unknown Hepatitis C Corrier Status Unknown	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 26 (5.41 per 100,000) 1 (0.21 per 100,000) 1 (0.33 per 100,000) 1 (0.34 per 100,000) 1 (0.35 per 100,000) 1 (0.35 per 100,000) 1 (0.35 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis C Chronic Carriers Hepatitis C Carrier Status Unknown Hepatitis C Chronic Carriers Malaria	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.33 per 100,000) 63 (13.1 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Acute Cases Hepatitis C Carrier Status Unknown Hepatitis C Carrier Status Unknown Hepatitis C Corrier Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive)	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (1.25 per 100,000) 1 (1.25 per 100,000) 1 (1.21 per 100,000) 6 (1.25 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Acute Cases Hepatitis C Carrier Status Unknown Hepatitis C Corrier Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive) Mumps	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.25 per 100,000) 17 (3.53 per 100,000) 17 (3.53 per 100,000) 16 (3.33 per 100,000) 16 (3.33 per 100,000) 16 (1.21 per 100,000) 16 (1.25 per 100,000) 16 (1.25 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Acute Cases Hepatitis C Carrier Status Unknown Hepatitis C Carrier Status Unknown Hepatitis C Corrier Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive) Mumps Pertussis	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.05 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 17 (3.53 per 100,000) 16 (3.33 per 100,000) 16 (3.33 per 100,000) 16 (3.33 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 5 (1.25 per 100,000) 5 (1.25 per 100,000) 5 (1.25 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Acute Cases Hepatitis C Carrier Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive) Mumps Pertussis Pneumococcal Disease (Invasive)	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.33 per 100,000) 1 (0.33 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.22 per 100,000) 1 (0.24 per 100,000) 5 (1.25 per 100,000) 5 (1.25 per 100,000) 2 (0.42 per 100,000) 3 (6.65 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Acute Cases Hepatitis C Carrier Status Unknown Hepatitis C Crimer Status Unknown Hepatitis C Crimer Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive) Mumps Pertussis Pneumococcal Disease (Invasive) Salmonellosis	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 16 (3.33 per 100,000) 16 (3.33 per 100,000) 16 (1.25 per 100,000) 16 (2.12 per 100,000) 16 (2.12 per 100,000) 15 (1.12 per 100,000) 16 (1.12 per 100,000) 16 (1.12 per 100,000) 16 (1.12 per 100,000) 17 (1.12 per 100,000) 18 (1.12 per 100,000) 19 (1.12 per 100,000) 19 (1.12 per 100,000) 10 (1.12 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Chronic Carriers Hepatitis B Chronic Carriers Hepatitis C Acute Cases Hepatitis C Carrier Status Unknown Hepatitis C Corrier Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive) Mumps Pertussis Pneumococcal Disease (Invasive) Salmonellosis Shigellosis	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.25 per 100,000) 17 (3.53 per 100,000) 16 (3.33 per 100,000) 16 (3.33 per 100,000) 16 (3.31 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.22 per 100,000) 5 (1.05 per 100,000) 5 (1.05 per 100,000) 2 (0.42 per 100,000) 3 (6.65 per 100,000) 8 (1.63 per 100,000) 18 (1.63 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Cute Cases Hepatitis C Carrier Status Unknown Hepatitis C Corrier Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive) Mumps Pertussis Pneumococcal Disease (Invasive) Salmonellosis Shigellosis Streptococcal Disease-Group A (Invasive/Severe)	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.25 per 100,000) 17 (3.53 per 100,000) 16 (3.35 per 100,000) 16 (3.35 per 100,000) 16 (3.35 per 100,000) 16 (2.12 per 100,000) 16 (2.12 per 100,000) 16 (3.25 per 100,000) 16 (3.25 per 100,000) 16 (3.25 per 100,000) 16 (3.25 per 100,000) 18 (3.26 per 100,000) 19 (3.26 per 100,000) 10 (3.26 per 100,000) 10 (3.26 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis C Acute Cases Hepatitis C Carriers Hepatitis C Carrier Status Unknown Hepatitis C Carrier Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive) Mumps Pertussis Pneumococcal Disease (Invasive) Salmonellosis Shigellosis Streptococcal Disease-Group A (Invasive/Severe) Varicella (Chickenpox)	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.33 per 100,000) 1 (0.33 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.22 per 100,000) 5 (1.25 per 100,000) 2 (0.42 per 100,000) 32 (6.65 per 100,000) 81 (16.84 per 100,000) 2 (0.42 per 100,000) 53 (11.02 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis B Chronic Carriers Hepatitis C Carrier Status Unknown Hepatitis C Carrier Status Unknown Hepatitis C Cronic Carriers Malaria Meningococcal Disease (Invasive) Mumps Pertussis Pneumococcal Disease (Invasive) Salmonellosis Shigellosis Streptococcal Disease-Group A (Invasive/Severe) Varicella (Chickenpox) Chlamydia	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 16 (3.33 per 100,000) 16 (3.33 per 100,000) 16 (3.33 per 100,000) 16 (3.25 per 100,000) 17 (3.25 per 100,000) 18 (16.84 per 100,000) 19 (3.25 per 100,000) 10 (3.25 per 100,000)	
Cryptosporidiosis E.Coli Giardiasis Haemophilus Influenzae-NonSerotype B Invasive Hepatitis A Hepatitis B Acute Cases Hepatitis B Carrier Status Unknown Hepatitis C Acute Cases Hepatitis C Carriers Hepatitis C Carrier Status Unknown Hepatitis C Carrier Status Unknown Hepatitis C Chronic Carriers Malaria Meningococcal Disease (Invasive) Mumps Pertussis Pneumococcal Disease (Invasive) Salmonellosis Shigellosis Streptococcal Disease-Group A (Invasive/Severe) Varicella (Chickenpox)	2020 2020 2020 2020 2020 2020 2020 202	106 (22.04 per 100,000) 7 (1.46 per 100,000) 14 (2.91 per 100,000) 14 (2.91 per 100,000) 5 (1.04 per 100,000) 5 (1.04 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.33 per 100,000) 1 (0.33 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.21 per 100,000) 1 (0.22 per 100,000) 5 (1.25 per 100,000) 2 (0.42 per 100,000) 32 (6.65 per 100,000) 81 (16.84 per 100,000) 2 (0.42 per 100,000) 53 (11.02 per 100,000)	

#### **Methodology and Notes**

#### Notes

1 The Banff-Jasper-Rocky Mountain House and Athabasca-Grande Prairie-Peace River Economic Regions consists of: 1 city, 69 towns, specialized municipalities, villages and summer villages, including the Municipality of Jasper; 30 municipal districts and improvement districts; and 44 Indian Reserves and Indian Settlements.

n/a = data not available; suppressed to meet the confidentiality requirements of the Statistics Act

 ${\hbox{\footnotesize COVID-19 numbers reflects change in government reporting; no longer reporting active cases.} \\$ 

All numbers are approximate. In certain instances (e.g., gender-based crimes), additional decimal spaces are shown in order to capture small numbers.

#### References

Alberta Transportation. 2022. Traffic Volumes at Points on the Highway Network. Website: Accessed: November 2022.

Government of Alberta. 2022. Alberta Major Projects List. Website: http://majorprojects.alberta.ca/. Accessed: December 2022.

Government of Alberta. 2021. 2021 Apartment Vacancy and Rental Cost Survey. 163pp.

Government of Alberta. 2021. Interactive Health Data Application [electronic database]. Retrieved from http://www.ahw.gov.ab.ca/IHDA\_Retrieval/. Accessed: November 2022.

Government of Alberta. 2022. Cases in Alberta. Website: https://www.alberta.ca/covid-19-alberta-data.aspx. Accessed: January 2023

Government of Canada. 2021. Canada Mortgage and Housing Corporation. Rental Market Report, 2020 Edition. Edmonton CMA, Data tables.

Website: https://www.cmhc-schl.gc.ca/en/professionals/housing-markets-data-and-research/housing-data/data-tables/rental-market/rental-market-report-data-tables. Accessed November 2022.

Statistics Canada. 2016. Census Profiles, 2016 Census. Website: http://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E. Accessed: June 2018.

Statistics Canada. 2020. Table 35-10-0183-01 Incident-based crime statistics, by detailed violations, police services in Alberta. Accessed: November 2022.

Statistics Canada. 2022. Table 14-10-0293-01 Labour force characteristics by economic region, three-month moving average, unadjusted for seasonality, last 5 months. Accessed: November 2022.